In 1996, Doug Olson was diagnosed with chronic lymphocytic leukemia (CLL) and underwent various treatments including chemotherapy. When the cancer stopped responding to treatment, he was recommended CAR T-cell therapy, a type of immunotherapy that reengineers immune cells to target cancer cells more effectively. CAR T-cell therapy has shown promising results for blood cancers, with a high rate of remission in some cases. Side effects include cytokine release syndrome and potential effects on the brain. While there are still challenges to overcome, CAR T-cell therapy has been a lifesaving treatment for many patients and shows potential for targeting solid tumors in the future.
Source link
What You Should Know Today
